Molecular Formula | C42H52N4O12 |
Molar Mass | 804.88 |
Melting Point | 138-140°C |
Boling Point | 603.2°C at 760 mmHg |
Flash Point | 318.6°C |
Solubility | Slightly soluble in water, soluble in methanol, slightly soluble in 2-propanol, practically insoluble in acetonitrile. |
Vapor Presure | 2.12E-15mmHg at 25°C |
Appearance | neat |
Color | White to off-white |
Maximum wavelength(λmax) | ['284nm(lit.)'] |
Merck | 14,4245 |
pKa | pKa1 7.9; pKa2 9.2(at 25℃) |
Storage Condition | Room temperature |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
Use | Used as a bronchodilator |
In vitro study | Formoterol is a potent airway smooth muscle relaxant with high potency, high affinity and selectivity for β2 adrenoceptors. Formoterol appears to remain in airway smooth muscle for a period of time, and due to its relaxing effect on human airway smooth muscle able to withstand repeated washes, formoterol exhibits a "reconfirmed" relaxing effect after washout of the β-adrenoceptor antagonist. In experimental test systems, Formoterol was shown to be able to effectively inhibit these cells and processes. Formoterol, such as salbutamol and salmeterol, relaxes guinea pig trachea and human bronchus in ex vivo preparation and concentration-dependently inhibits antigen-induced release of inflammatory mediators from human lung slices. |
In vivo study | Dose-related inhibition of histamine-induced bronchoconstriction by Formoterol in conscious guinea pigs. In guinea pigs, Formoterol inhibited histamine-induced plasma protein exudation (PPE), with significant inhibition observed at doses of 10 mg/mL and 100 mg/ml. In guinea pig lung, Formoterol (100 mg/ml) inhibited PPE for 2-4 hours, between previously obtained salbutamol (1 hour) and salmeterol (> 6 hours). In guinea pig lung, Formoterol inhibits neutrophil aggregation (lipopolysaccharide-induced), but requires higher doses than inhibition of granulocyte-independent PPE (histamine-induced). Formoterol (100 mg/ml) inhibited PAF-induced eosinophil aggregation in guinea pig lung. |
UN IDs | 3249 |
RTECS | LQ2988000 |
Hazard Class | 6.1(b) |
Packing Group | II |
Toxicity | LD50 in male, female, rats, mice (mg/kg): 3130, 5580, 6700, 8310 orally; 98, 100, 72, 71 i.v.; 1000, 1100, 640, 670 s.c.; 170, 210, 240, 210 i.p. (Yoshida) |